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Background: Fibrinogen concentrate treatment can improve coagulation during massive traumatic bleeding. The
aim of this in vitro study was to determine whether fibrinogen concentrate, or a combination of factor XIII and
fibrinogen concentrates, could reverse a haemodilution-induced coagulopathy during hypothermia.
Methods: Citrated venous blood from 10 healthy volunteers was diluted in vitro by 33% with 130/0.42 hydroxyethyl
starch (HES) or Ringer’s acetate (RAc). The effects of fibrinogen concentrate corresponding to 4 gram per 70 kg, or a
combination of the same dose of fibrinogen with factor XIII (20 IU per kg), were measured using rotational
thromboelastometry (ROTEM). The blood was analysed at 33°C or 37°C with ROTEM EXTEM and FIBTEM reagents.
Clotting time (CT), clot formation time (CFT), alpha angle (AA) and maximal clot formation (MCF) were recorded.
Results: Fibrinogen with or without factor XIII improved all ROTEM parameters in either solution irrespective of
temperature, with the exception of EXTEM-AA and EXTEM-CFT in HES haemodilution. Fibrinogen increased
FIBTEM-MCF more in the samples diluted with RAc than HES, particularly in presence of factor XIII.
Conclusions: Fibrinogen improved in vitro haemodilution-induced coagulopathy at both 33°C and 37°C, though
more efficiently after crystalloid than HES haemodilution. Factor XIII had an additional effect on FIBTEM-MCF, but
only after crystalloid dilution.
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Haemodilution and hypothermia both contribute to co-
agulopathy and aggravate acute traumatic coagulopathy,
which has been recognized as a significant cause of death
in patients with traumatic injuries [1]. We therefore stud-
ied the efficacy of concentrates of fibrinogen and factor
XIII (FXIII) in improving in vitro coagulopathy induced
by haemodilution and hypothermia.
Hypothermia impairs coagulation mainly by platelet
inhibition [2], whereas haemodilution principally impairs
plasma coagulation [3]. In addition to the dilutional ef-
fects seen with crystalloids, synthetic colloid solutions
impair fibrinogen polymerization and platelet function [3].
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unless otherwise stated.has been studied extensively with whole blood viscoelastic
haemostatic assays (VHA) such as thromboelastometry
(ROTEM), but there are few studies of simultaneous
hypothermia and haemodilution [4,5]. In addition, in vitro
correction of haemodilution-induced coagulopathy with
fibrinogen concentrate has been studied extensively [6,7],
but not during hypothermia. Previous in vitro studies indi-
cate an additional effect of high doses of FXIII together
with fibrinogen to correct haemodilution-induced coagu-
lopathy, but this needs to be studied at clinically relevant
dosages [7-9]. Therefore, the purpose of this study was to
evaluate the in vitro effects of mild hypothermia in the
context of coagulopathy induced by haemodilution with
crystalloid or hydroxyethyl starch solutions; and the effects
of fibrinogen concentrate, alone or in combination with
factor XIII concentrate using ROTEM, a well-known
VHA. The primary hypothesis was that fibrinogen con-
centrate, with or without factor XIII, reduce dilutionalal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Ten healthy individuals (one woman and nine men, age
27–65 years) gave their written informed consent to par-
ticipate in this study. None of the subjects received any
medication in the preceding 7 days and none had a his-
tory of coagulopathy. The Regional Ethical Review Board
in Lund, Sweden, approved the study (DNR 2008:484).
Sampling
Blood was sampled into citrated plastic vacuum tubes
(BD Vacutainer® Coagulation Tube, PET, 0.3 ml 0.109 M
citrate). Venepuncture with minimal stasis was conducted,
using a 21 Gauge needle, and the first tube was dis-
carded. The samples were incubated at 33°C or 37°C for
30 minutes to ensure temperature equilibration and ana-
lysed within 4 hours of sampling.
Hypothermia and haemodilution
A digital thermometer submerged into a fluid-filled ref-
erence tube was used to check all blood sample temper-
atures. The ROTEM instruments were set at either 33°C
or 37°C. The blood samples were diluted 2:1 volume
by volume with either Ringer’s acetated solution (RAc;
Fresenius Kabi, Bad Homburg, Germany(G)) or 6% hydro-
xyethyl starch in saline (HES; MW 130 kDa, substitution
ratio 0.42, Venofundin®, B.Braun, Melsungen, G) that is
33% haemodilution.
Fibrinogen and factor XIII
Human fibrinogen concentrate (Riastap®, CSL Behring
Marburg, G) and factor XIII (FXIII) concentrate (Fibro-
gammin®; now registered as Cluvo®, CSL Behring) were
dissolved according to the manufacturer’s instructions,
giving concentrations of 20 mg/ml and 62.5 IU/ml re-
spectively. 120 μl of fibrinogen concentrate or 120 μl of
fibrinogen +15 μl of FXIII were added to the respective
blood sample, to a total sample volume of 3000 μl. These
dosages correspond to 4 g of fibrinogen and 1550 IU of
FXIII to a 70-kg man or 55 mg fibrinogen and 22 IU FXIII
per kg of body weight. The FXIII dosage followed recom-
mendations from the manufacturer on how to treat haem-
orrhage in congenital FXIII-deficient patients (10–20 IU/kg
of body weight). The 4 g fibrinogen dosage is in line with
current guidelines on treatment of massive bleeding.
ROTEM
Rotational thromboelastometry (ROTEM®; Pentapharm,
Munich, Germany), a viscoelastic coagulation analysis
instrument, was used according to the manufacturer’s
instructions. Two ROTEM assays, EXTEM and FIBTEM,were used. Coagulation was stimulated with tissue factor
in the EXTEM test and the following parameters were
recorded: clotting time (CT), clot formation time (CFT),
alpha-angle (AA) and maximal clot formation (MCF). The
following EXTEM parameters measure the clot velocity:
CT shows how long clot initiation takes while CFT and
AA reflect the clot amplification and propagation. EXTEM-
MCF measures the maximal clot strength and is dependent
on platelet count and function, as well as fibrin formation
and polymerisation. The FIBTEM test is identical to the
EXTEM test except for that cytochalacin D, a platelet
inhibitor is added to the test reagent. This results in
FIBTEM-MCF representing clot strength dependent on
fibrin formation and polymerization alone. The only
FIBTEM parameter recorded was FIBTEM-MCF. The last
parameter EX-FIBTEM-MCF is a surrogate measure of
platelet activity, which is calculated as FIBTEM-MCF sub-
tracted from EXTEM-MCF.
Statistical analysis
For all statistical calculations the software package R,
version 3.0.0, was used [10]. Repeated measures were
analysed using univariate mixed models, using the pack-
age nlme ver. 3.1-109 [11]. Heterogeneous variances were
evaluated with weighting. Post-hoc comparisons were made
using the Multcomp package ver. 1.2-17 [12] using false
discovery rate adjustment of p-values [13]. Data were
analysed in two steps. The first step with haemodilution
(control, RAc, HES) and two different temperatures
(33°C, 37°C) sought to evaluate the potentially different
effects of haemodilution with different solutions on normo-
and hypothermic blood respectively. The second step used
haemodilution with two different solutions (RAc, HES),
two temperatures (33°C, 37°C) and the addition of co-
agulation factors (control, fibrinogen, fibrinogen + FXIII);
this analysis evaluated the potential interaction between




In the undiluted samples, all EXTEM parameters and
FIBTEM-MCF were within the normal range at 37°C [14].
Hypothermia and haemodilution
All clot velocity parameters were impaired by hypothermia
of 33°C: in both undiluted and diluted blood CT and
CFT were prolonged and AA was decreased (Figure 1).
EXTEM-MCF decreased to a small extent during hypo-
thermia, but only during concurrent haemodilution with ei-
ther solution (Figure 2). Despite these hypothermic effects,
the average values in undiluted samples were still mainly
within the normal range at 33°C: a few samples’ EXTEM-
CFT exceeded the reference range and EXTEM-AA and
Figure 1 Effects of hypothermia (33° vs. 37 C) and haemodilution
on the ROTEM EXTEM parameters clotting time (CT), clot formation
time CFT) and alpha angle (AA). RAc: Ringer’s acetate, HES:
hydroxyethyl starch. All differences between haemodilution groups
(Undiluted vs. RAc, Undiluted vs. HES, and RAc vs. HES) within each
temperature were significant (P < 0.001), except the differences of CT
between Undiluted and RAc at both temperatures, which were not
significant. Brackets show significant differences between temperatures.
(+: P< 0.05, ++: P< 0.01, +++: P< 0.001). Data are presented as mean
values, error bars are 95% simultaneous confidence intervals. N = 10.
Figure 2 Effects of hypothermia (33° vs. 37 C) and haemodilution
on the ROTEM parameters. EXTEM-MCF, FIBTEM-MCF and
EX-FIBTEM-MCF; the latter calculated as FIBTEM-MCF subtracted from
EXTEM-MCF. RAc: Ringer’s acetat, HES: hydroxyethyl starch. All differences
of EXTEM-MCF and FIBTEM-MCF between haemodilution groups
(Undiluted vs. RAc, Undiluted vs. HES, and RAc vs. HES) within each
temperature were significant (P < 0.001), except the difference of
FIBTEM-MCF between Undiluted and RAc at 33°C. Differences of
EX-FIBTEM-MCF were only significant (P < 0.001) between Undiluted
and haemodilution with either RAc or HES, at 33°C. Brackets show
significant differences between temperatures. (+: P < 0.05, ++: P <
0.01, +++: P < 0.001). Data are presented as mean values, error bars
are 95% simultaneous confidence intervals. N = 10.
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the samples.
At normothermia, haemodilution with HES signifi-
cantly impaired all measured parameters, whereas RAcsignificantly impaired all parameters except CT. In addition,
HES impaired ROTEM parameters significantly more than
RAc (Figures 1 and 2). Moreover, the combination of
Winstedt et al. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine 2014, 22:73 Page 4 of 8
http://www.sjtrem.com/content/22/1/73hypothermia and HES haemodilution interacted to im-
pair CFT and AA in relation to undiluted samples (CFT:
P < 0.001 and AA: P < 0.05), as well as in relation to RAc
haemodiluted samples (CFT: P < 0.001 and AA: P < 0.01).Addition of fibrinogen with or without factor XIII
Addition of fibrinogen concentrate to haemodiluted sam-
ples enhanced coagulation in general, except for CFT and
AA in HES-haemodiluted samples. With FIBTEM-MCF
and EXTEM-AA, there were significant interactions be-
tween fibrinogen concentrate and RAc haemodilution as
compared to HES haemodilution, that is FIBTEM-MCF
and AA were more effectively increased during RAc hae-
modilution than during HES haemodilution (P < 0.05 at
both temperatures with FIBTEM-MCF and P < 0.05 at
37°C with AA) (Figures 3 and 4).
Almost all the parameters were improved to the same
degree by fibrinogen combined with FXIII, as by fibrinogen
alone. However, FXIII had additional effects to the fibrino-
gen effects during RAc haemodilution; AA increased more
at 33°C and FIBTEM-MCF increased more at both 33° and
37°C after addition of fibrinogen + FXIII as compared with
fibrinogen alone (Figures 3 and 4). The better effect of fi-
brinogen combined with FXIII on FIBTEM-MCF is also
demonstrated by significant synergies between RAc hae-
modilution and fibrinogen + FXIII as compared to control
(P < 0.001 at both temperatures) as well as compared to fi-
brinogen alone (P < 0.05 at both temperatures).Figure 3 Effects of coagulation factor concentrate (Fibrinogen or
Fibrinogen with factor XIII (FXIII)) at two different temperatures
(33° vs. 37 C) during haemodilution with Ringer’s acetate (RAc) or
hydroxyethyl starch (HES). ROTEM EXTEM parameters shown arePlatelet dependent clot strength (EX-FIBTEM-MCF)
The platelet dependent clot strength (EX-FIBTEM-MCF)
was 72% and 76% of the EXTEM-MCF, at 37°C and
33°C respectively. Hypothermia at 33°C and haemodilu-
tion in combination decreased EX-FIBTEM-MCF, but
hypothermia or haemodilution alone had no effect on EX-
FIBTEM-MCF. HES and RAc affected EX-FIBTEM-MCF
to the same extent (Figure 2). Addition of fibrinogen
or fibrinogen + FXIII did not significantly change
EX-FIBTEM-MCF with HES haemodilution, whereas
EX-FIBTEM-MCF significantly decreased after adding
fibrinogen + FXIII during RAc haemodilution (Figure 4).clotting time (CT), clot formation time CFT) and alpha angle (AA).
Statistically significant differences are marked with brackets. All
significances are P < 0.001, except where elsewise stated; +: P <
0.05, ++: P < 0.01. Data are presented as mean values, error bars
are 95% simultaneous confidence intervals. N = 10.Discussion
Principal findings
Our principal finding is that fibrinogen concentrate, with
or without factor XIII concentrate, reduces dilutional co-
agulopathy irrespective of temperature (33° or 37°C) and
that this effect was more pronounced with RAc than
HES haemodilution. We also found that hypothermia af-
fects coagulation more during haemodilution with HES
than with RAc.Hypothermia and haemodilution
The effects of cooling undiluted blood to 33°C on
ROTEM parameters were small. Although significant
impairments of clot initiation (CT) and propagation
(CFT, AA) were seen, measures of clot strength (EXTEM-
MCF and FIBTEM-MCF) were unaffected. These results
Figure 4 Effects of coagulation factor concentrate (Fibrinogen or
Fibrinogen with factor XIII (FXIII)) at two different temperatures
(33° vs. 37 C) during haemodilution with Ringer’s acetate
(RAc) or hydroxyethyl starch (HES). ROTEM parameters shown
are EXTEM-MCF, FIBTEM-MCF and EX-FIBTEM-MCF; the latter calculated
as FIBTEM-MCF subtracted from EXTEM-MCF. Statistically significant
differences are marked with brackets. All significances are P< 0.001, except
where elsewise stated; +: P< 0.05, ++: P< 0.01. Data are presented as
mean values, error bars are 95% simultaneous confidence intervals. N = 10.
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VHA’s, which demonstrate mild to moderate hypothermia
to decrease the rate of clot formation but not the clot
strength [15,16], even though more severe hypothermia
(<28°C) may decrease clot strength [17]. An in vitro study
on the relative effects of hypothermia on platelets andplasma coagulation indicated an impaired platelet adhe-
sion as the primary cause of coagulopathy during mild
hypothermia [2]. This may explain our previous results
with free oscillation rheometry (FOR), which measured
a decreased clot velocity as well as clot strength during
hypothermia [9]. ROTEM is possibly better at detecting
plasma coagulation than platelet function whereas FOR
is more sensitive to platelet function.
The observations that haemodilution impaired param-
eters reflecting both the rate of clot formation and clot
strength, and that HES attenuated these parameters more
than RAc, is in line with previous research [18,19]. Nu-
merous studies with VHA’s have shown a progressive
decrease of initiation, amplification and propagation of
coagulation as well as clot strength, where clot strength
was more affected by synthetic colloids than crystalloids
[9,20,21]. Synthetic colloids, such as gelatine and HES,
interfere with fibrin network structure and consequently
decrease clot strength more than explained by dilution of
plasma proteins alone [22]. In contrast, some investiga-
tions have shown that haemodilution up to 50% with
isotonic saline may induce a hypercoagulable state [23].
This has been suggested to be caused by decreased
plasma antithrombin levels [24]. However, these studies
used native non-activated blood, which may explain the
difference from our results [25].
Hypothermia in combination with haemodilution mainly
affected ROTEM parameters measuring clot velocity.
Thus, HES haemodilution interacted with hypothermia
to further impair CFT and AA. This is in line with our
previous study with free oscillation rheometry (FOR)
[9], but few other studies have addressed the combined
effect of haemodilution and hypothermia. A study from
1994 measuring activated partial thromboplastin time
found additional but not synergistic effects of hypothermia
and haemodilution with a crystalloid [5]. Possible explana-
tions for the observed synergy between hypothermia and
HES, may be that both hypothermia [2,26] and HES
[27,28] have direct effects on platelets, and that also
plasma coagulation activity is decreased during both
hypothermia [2] and haemodilution [29]. Platelet acti-
vation is very important for the thrombin burst associ-
ated with propagation of coagulation, which may explain
why the ROTEM parameters CFT and AA were particu-
larly affected by the combination of HES-haemodilution
and hypothermia.
Addition of fibrinogen with or without factor XIII
Our results imply that fibrinogen concentrate can be used
to improve coagulation at 33°C. This was also suggested,
albeit not statistically significantly, in our previous study
with FOR [9]. The results from the present study also
imply that a clot weakened by RAc is easier to improve
than a clot weakened by HES, which corroborates results
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improved fibrinogen-dependent clot strength (FIBTEM-
MCF) irrespective of fluid or temperature, this improve-
ment was greater during RAc than HES haemodilution.
The general view that hypothermia-induced coagulopathy
is refractory to treatment with coagulation factor con-
centrates [32] is contradicted by our results, as well as
by a previous study where fibrinogen concentrate in-
creased whole blood coagulation at 32°C [33]. It is a
principal finding of our study, that the clot stabilizing
effect of fibrinogen concentrate on coagulopathy induced
by RAc is as effective at 33°C as it is during normother-
mia. This implies that correction of hypothermia before
substitution with fibrinogen concentrate is clinically not
necessary.
Factor XIII improved fibrinogen’s effect on FIBTEM-
MCF during RAc-haemodilution but not during HES
haemodilution. In line with our study, several previous
in vitro haemodilution studies on healthy volunteers have
shown that although FXIII alone does not improve dilu-
tional coagulopathy, it can enhance fibrinogen’s corrective
effect [7-9,34]. These results contradict an in vitro study
on blood from intensive care patients where supraphysio-
logical doses of FXIII were used [35]. In this study, a high
pre-existing concentration of fibrinogen in plasma may
explain the corrective effect of FXIII alone. It is probably
only worthwhile to administer factor XIII to correct a
coagulopathy if normalizing plasma fibrinogen concen-
trations is cared for. Consequently, it may be of value to
combine fibrinogen with factor XIII in order to improve
clot stability during RAc-haemodilution.
Platelet dependent clot strength (EX-FIBTEM-MCF)
The derived parameter EX-FIBTEM-MCF is considered
to reflect platelet dependent clot strength. EX-FIBTEM-
MCF decreased both after haemodilution and mild
hypothermia. This is in line with studies using the
cone and platelet analyser, where haemodilution [18]
and mild hypothermia [2] showed reduced platelet ag-
gregation. In contrast, some studies have found hypothermia
to increase platelet aggregation, as measured with imped-
ance aggregometry [36,37]. Aggregation is a process where
fibrinogen stick platelets to each other through the platelet
receptor glycoprotein IIb/IIIa, and fibrinogen concentrate
has previously been shown to counteract glycoprotein
IIb/IIIa–directed platelet inhibition [38]. We therefore
expected the hypothermia induced reduction of platelet
dependent clot strenght to be reversed by fibrinogen
concentrate, but instead, EX-FIBTEM-MCF decreased
significantly after the addition of fibrinogen + FXIII con-
centrates to RAc diluted blood. A recent study found plate-
let aggregation to be reduced or unaffected by in vitro
supplementation with fibrinogen concentrate, depend-
ing on which platelet activator being used [39]. However,we believe that the reduction of EX-FIBTEM-MCF should
not be interpreted as a decreased platelet function but that
the addition of fibrinogen + FXIII increased FIBTEM-MCF
values more than EXTEM-MCF, and hence the so called
platelet dependent clot strength (EX-FIBTEM-MCF)
decreased regardless of actual platelet function. There
are principally two possible explanations of this short-
coming of ROTEM: 1) the ROTEM instrument may be
more sensitive to changes at low levels of clot strength
(MCF) than at normal levels; or 2) platelets are not
fully inhibited by the FIBTEM assay. ROTEM uses forced
oscillation and an arbitrary clot strength scale with a the-
oretical maximum of 100 mm, which makes a limited
sensitivity at the upper scale possible. Platelet inhibition
with cytochalacin D has been shown to be improved if
combined with abciximab, a fibrinogen receptor inhibitor
[40]. In conclusion, we and others question the reliability
of EX-FIBTEM-MCF as a platelet function parameter [41]
and suggest that other methods may be more suitable.
Limitations
There are several methodological concerns when perform-
ing in vitro coagulation tests. For example, there is no acti-
vation of procoagulative or fibrinolytic responses secondary
to tissue trauma [1]. Furthermore, shear strains applied
with viscoelastic haemostatic assays such as ROTEM
are substantially lower than those found in the human
circulation, which may modify clot structure during mea-
surements [42]. There are also concerns with in vitro
haemodilution: acid–base regulation is not physiological
and the decreased haematocrit may increase fibrin thread
formation in the reaction chamber [43]. Therefore, we
restricted dilution to 33%. Finally, there is much debate
regarding the use of native whole blood versus citrated
whole blood in VHAs. We used citrated blood, since it
can be incubated and stored for up to four hours whereas
native blood must be analysed within 4 minutes. However,
incubation of citrated blood over 30 minutes has been
shown to decrease thrombelastographic differences between
native and citrate blood analyses [25].
Conclusion
In conclusion, our results show that fibrinogen with or
without FXIII corrected in vitro dilutional coagulopathy
also during hypothermia and that the corrective effects
were weaker during haemodilution with HES, as compared
to RAc. Factor XIII enhanced the corrective effects of
fibrinogen, but only during RAc haemodilution. Finally,
HES haemodilution interacted with hypothermia to im-
pair coagulation.
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